|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Nov 30, 2025
|
Q3 FY2025
As of Aug 31, 2025
|
Q2 FY2025
As of May 31, 2025
|
Q1 FY2025
As of Feb 28, 2025
|
Q4 FY2024
As of Nov 30, 2024
|
Q3 FY2024
As of Aug 31, 2024
|
Q2 FY2024
As of May 31, 2024
|
Q1 FY2024
As of Feb 29, 2024
|
Q4 FY2023
As of Nov 30, 2023
|
Q3 FY2023
As of Aug 31, 2023
|
Q2 FY2023
As of May 31, 2023
|
Q1 FY2023
As of Feb 28, 2023
|
Q4 FY2022
As of Nov 30, 2022
|
Q3 FY2022
As of Aug 31, 2022
|
Q2 FY2022
As of May 31, 2022
|
Q1 FY2022
As of Feb 28, 2022
|
Q4 FY2021
As of Nov 30, 2021
|
Q3 FY2021
As of Aug 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||||||||||||||
| Cash and equivalents | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Contingency receivable | ||||||||||||||||||||
| Prepaids and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||||||||||||||
| Current liabilities | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Nonrelated Party | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total accounts payable and accrued expenses | ||||||||||||||||||||
| Loan payable - D&O insurance | ||||||||||||||||||||
| Convertible note, net of discount | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Promissory notes | ||||||||||||||||||||
| Related party loan | ||||||||||||||||||||
| Related Party | ||||||||||||||||||||
| Total related party loan | ||||||||||||||||||||
| Shares unissued liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Common stock, $0.001 par value, 75,000,000 shares authorized; 5,092,023 and 4,654,200 shares issued and outstanding as of August 31, 2021 and November 30, 2020, respectively | ||||||||||||||||||||
| Total Liabilities | ||||||||||||||||||||
| Stockholders’ deficit | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Series B Preferred Stock | ||||||||||||||||||||
| Total preferred stock, value | ||||||||||||||||||||
| Common stock, authorized 1,000,000,000 shares, $.001 par value, 824,074,734 and 716,021,604 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Subscription receivable | ||||||||||||||||||||
| Treasury stock | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficit | ||||||||||||||||||||
| Total liabilities and stockholders’ deficit | ||||||||||||||||||||
Loading...
